US2005142202A1PendingUtilityA1

Compositions for achieving a therapeutic effect in an anatomical structure

62
Priority: Feb 12, 2001Filed: Dec 17, 2004Published: Jun 30, 2005
Est. expiryFeb 12, 2021(expired)· nominal 20-yr term from priority
Inventors:Wouter E. RoordaStephen D. Pacetti
A61P 9/00A61K 9/1647A61K 9/1694A61K 47/36A61P 29/00A61K 9/14A61K 9/1617A61K 31/727A61K 47/26A61K 48/00A61K 9/1658A61K 31/573A61K 38/1825
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods of using the compositions to achieve a therapeutic effect are provided.

Claims

exact text as granted — not AI-modified
1 - 31 . (canceled)  
     
     
         32 . A particle to form an embolus within a region of an anatomical lumen, the particle including a material that allows a portion of the particle to degrade or allows the particle to disintegrate into fragments so that the particle can form multiple emboli at different points of time within the anatomical lumen.  
     
     
         33 . The particle of  claim 32 , wherein the material allows a diameter of the particle to be reduced.  
     
     
         34 . The particle of  claim 32 , wherein the material allows the particle to degrade or to disintegrate into fragments in less than seven days.  
     
     
         35 . The particle of  claim 32 , wherein the material allows the particle to degrade or to disintegrate into fragments in a duration of time that does not allow for cellular damage or cell death in the region of the anatomical lumen being treated by the particle.  
     
     
         36 . The particle of  claim 32 , further including a therapeutic substance.  
     
     
         37 . The particle of  claim 36 , wherein the therapeutic substance is selected from the group consisting of antineoplastic, antiplatelet, anticoagulant, fibrinolytic, antimitotic, thrombin inhibitor, antiinflammatory, antiproliferative, antioxidant, antiangiogenic, angiogenic, arteriogenic and antiallergic substances, and mixtures thereof.  
     
     
         38 . The particle of  claim 36 , wherein the particle is configured to release the therapeutic substance.  
     
     
         39 . The particle of  claim 32 , wherein the material is selected from the group consisting of a disintegrant, a water soluble polymer, a biodegradable inorganic substance, and mixtures thereof.  
     
     
         40 . The particle of  claim 39 , wherein the material is a disintegrant selected from the group consisting of croscarmellose, povidone, lactose, and mannose.  
     
     
         41 . The particle of  claim 39 , wherein the material is a biodegradable inorganic substance selected from the group consisting of hydroxyapatite, dahlite, brushite, calcium sulphate, octacalcium phosphate, amorphous calcium phosphate and beta-tricalcium phosphate.  
     
     
         42 . The particle of  claim 32 , wherein the material is a hygroscopic substance.  
     
     
         43 . The particle of  claim 32 , further including a polymeric material.  
     
     
         44 . A particle to form an embolus within a region of an anatomical lumen, comprising a disintegrant, wherein the disintegrant allows the particle to form the embolus within the region for a transitory period.  
     
     
         45 . The particle of  claim 44 , wherein the disintegrant is selected from the group consisting of croscarmellose, povidone, lactose, and mannose.  
     
     
         46 . The particle of  claim 44 , wherein the disintegrant is a hygroscopic substance.  
     
     
         47 . The particle of  claim 44 , further comprising a therapeutic substance.  
     
     
         48 . The particle of  claim 47 , wherein the therapeutic substance is selected from the group consisting of antineoplastic, antiplatelet, anticoagulant, fibrinolytic, antimitotic, thrombin inhibitor, antiinflammatory, antiproliferative, antioxidant, antiangiogenic, angiogenic, arteriogenic and antiallergic substances, and mixtures thereof.  
     
     
         49 . The particle of  claim 47 , wherein the particle is configured to release the therapeutic substance.  
     
     
         50 . The particle of  claim 44 , further comprising a polymeric material.  
     
     
         51 . The particle of  claim 44 , wherein the transitory period is less than seven days.  
     
     
         52 . The particle of  claim 44 , wherein the transitory period is less than the duration which results in cell damage or cell death in the region of the anatomical lumen being treated by the particle.  
     
     
         53 . The particle of  claim 44 , wherein the disintegrant allows a diameter of the particle to be reduced.  
     
     
         54 . The particle of  claim 44 , wherein the disintegrant allows the particle to disintegrate into fragments.  
     
     
         55 . The particle of  claim 44 , wherein the disintegrant is dispersed within the particle.  
     
     
         56 . The particle of  claim 44 , wherein the disintegrant is concentrated at one or more areas of the particle.  
     
     
         57 . A particle to form an embolus within a region of an anatomical lumen, comprising a water soluble polymer and a hydrophobic counterion, wherein the water soluble polymer allows the particle to form the embolus within the region for a transitory period.  
     
     
         58 . The particle of  claim 57 , wherein the transitory period is less than seven days.  
     
     
         59 . The particle of  claim 57 , wherein the transitory period is less than the duration which results in cell damage or cell death in the region of the anatomical lumen being treated by the particle.  
     
     
         60 . The particle of  claim 57 , wherein the water soluble polymer allows a diameter of the particle to be reduced.  
     
     
         61 . The particle of  claim 57 , wherein the water soluble polymer allows the paticle to disintegrate into fragments.  
     
     
         62 . The particle of  claim 57 , further comprising a therapeutic substance.  
     
     
         63 . The particle of  claim 62 , wherein the therapeutic substance is selected from the group consisting of antineoplastic, antiplatelet, anticoagulant, fibrinolytic, antimitotic, thrombin inhibitor, antiinflammatory, antiproliferative, antioxidant, antiangiogenic, angiogenic, arteriogenic and antiallergic substances, and mixtures thereof.  
     
     
         64 . The particle of  claim 62 , wherein the particle is configured to release the therapeutic substance.  
     
     
         65 . A composition for therapeutic treatment, comprising a particle including a biodegradable compressed material, the particle configured to form an embolus within a region of an anatomical lumen.  
     
     
         66 . The composition of  claim 65 , wherein the particle further includes a therapeutic substance.  
     
     
         67 . The composition of  claim 66 , wherein the therapeutic substance is selected from the group consisting of antineoplastic, antiplatelet, anticoagulant, fibrinolytic, antimitotic, thrombin inhibitor, antiinflammatory, antiproliferative, antioxidant, antiangiogenic, angiogenic, arteriogenic and antiallergic substances, and mixtures thereof.  
     
     
         68 . The composition of  claim 66 , wherein the particle is configured to release the therapeutic substance.  
     
     
         69 . The composition of  claim 65 , wherein the particle further includes a polymeric material.  
     
     
         70 . The composition of  claim 65 , wherein the biodegradable compressed material includes a fatty acid or a wax.  
     
     
         71 . A particle to form an embolus within a region of an anatomical lumen, comprising a biodegradable inorganic substance, wherein the biodegradable inorganic substance allows the particle to form the embolus within the region for a transitory period.  
     
     
         72 . The particle of  claim 71 , wherein the biodegradable inorganic substance is selected from the group consisting of hydroxyapatite, dahlite, brushite, calcium sulphate, octacalcium phosphate, amorphous calcium phosphate and beta-tricalcium phosphate.  
     
     
         73 . The particle of  claim 71 , wherein the transitory period is less than seven days.  
     
     
         74 . The particle of  claim 71 , wherein the transitory period is less than the duration which results in cell damage or cell death in the region of the anatomical lumen being treated by the particle.  
     
     
         75 . The particle of  claim 71 , wherein the biodegradable inorganic substance allows a diameter of the particle to be reduced.  
     
     
         76 . The particle of  claim 71 , wherein the biodegradable inorganic substance causes the particle to disintegrate into fragments.  
     
     
         77 . The particle of  claim 71 , further comprising a therapeutic substance.  
     
     
         78 . The particle of  claim 77 , wherein the therapeutic substance is selected from the group consisting of antineoplastic, antiplatelet, anticoagulant, fibrinolytic, antimitotic, thrombin inhibitor, antiinflammatory, antiproliferative, antioxidant, antiangiogenic, angiogenic, arteriogenic and antiallergic substances, and mixtures thereof.  
     
     
         79 . The particle of  claim 77 , wherein the particle is configured to release the therapeutic substance.  
     
     
         80 . The particle of  claim 71 , further comprising a polymeric material.  
     
     
         81 . A composition for a therapeutic treatment, comprising a particle including a surfactant and a therapeutic substance, the particle configured to form an embolus within a region of an anatomical lumen.  
     
     
         82 . The composition of  claim 81 , wherein the surfactant is selected from the group consisting of sorbitan monooleate, polyoxyethylene trioleate, and poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) triblock copolymers.  
     
     
         83 . The composition of  claim 81 , wherein the therapeutic substance is selected from the group consisting of antineoplastic, antiplatelet, anticoagulant, fibrinolytic, antimitotic, thrombin inhibitor, antiinflammatory, antiproliferative, antioxidant, antiangiogenic, angiogenic, arteriogenic and antiallergic substances, and mixtures thereof.  
     
     
         84 . The composition of  claim 81 , wherein the particle is configured to release the therapeutic substance.

Join the waitlist — get patent alerts

Track US2005142202A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.